SI2101777T1 - Sestavek za zdravljenje pljučne hipertenzije - Google Patents

Sestavek za zdravljenje pljučne hipertenzije

Info

Publication number
SI2101777T1
SI2101777T1 SI200731668T SI200731668T SI2101777T1 SI 2101777 T1 SI2101777 T1 SI 2101777T1 SI 200731668 T SI200731668 T SI 200731668T SI 200731668 T SI200731668 T SI 200731668T SI 2101777 T1 SI2101777 T1 SI 2101777T1
Authority
SI
Slovenia
Prior art keywords
treating
composition
pulmonary hypertension
hypertension
pulmonary
Prior art date
Application number
SI200731668T
Other languages
English (en)
Slovenian (sl)
Inventor
Michael J. Gerber
Christopher Dufton
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39092031&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2101777(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of SI2101777T1 publication Critical patent/SI2101777T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200731668T 2006-12-12 2007-12-11 Sestavek za zdravljenje pljučne hipertenzije SI2101777T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86966706P 2006-12-12 2006-12-12
PCT/US2007/087058 WO2008073928A1 (en) 2006-12-12 2007-12-11 Composition for treating a pulmonary hypertension
EP07855065.4A EP2101777B1 (en) 2006-12-12 2007-12-11 Composition for treating a pulmonary hypertension

Publications (1)

Publication Number Publication Date
SI2101777T1 true SI2101777T1 (sl) 2015-08-31

Family

ID=39092031

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200731668T SI2101777T1 (sl) 2006-12-12 2007-12-11 Sestavek za zdravljenje pljučne hipertenzije

Country Status (15)

Country Link
US (7) US20080139593A1 (enExample)
EP (2) EP2952193A1 (enExample)
JP (1) JP2010512414A (enExample)
AU (1) AU2007333115B2 (enExample)
CA (1) CA2669536C (enExample)
CY (1) CY2016017I1 (enExample)
DK (1) DK2101777T3 (enExample)
ES (1) ES2544724T3 (enExample)
HK (1) HK1218393A1 (enExample)
HU (2) HUE025355T2 (enExample)
LU (1) LU93081I2 (enExample)
PL (1) PL2101777T3 (enExample)
PT (1) PT2101777E (enExample)
SI (1) SI2101777T1 (enExample)
WO (1) WO2008073928A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010512414A (ja) * 2006-12-12 2010-04-22 ギリード・コロラド・インコーポレーテッド 肺高血圧を処置するための組成物
CN101815534A (zh) 2007-07-11 2010-08-25 莱西肯医药有限公司 用于治疗肺动脉高压以及相关疾病和病症的方法和组合物
CN101801936B (zh) * 2007-07-31 2012-10-03 吉利德科罗拉多公司 安立生坦的代谢物和衍生物
WO2010062640A1 (en) * 2008-10-28 2010-06-03 Gilead Colorado, Inc. Methods for treating idiopathic pulmonary fibrosis and associated complications
KR20130088834A (ko) * 2010-06-30 2013-08-08 길리애드 사이언시즈, 인코포레이티드 폐 고혈압의 치료를 위한 ａ２ｂ 아데노신 수용체 길항제의 용도
EA026074B1 (ru) * 2010-10-15 2017-02-28 Джилид Сайэнс, Инк. Способы, включающие применение композиции амбризентана и тадалафила для лечения легочной артериальной гипертензии
WO2013024022A1 (en) * 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary hypertension
US20130225595A1 (en) * 2012-02-29 2013-08-29 Gilead Sciences, Inc. Method for treating pulmonary arterial hypertension in a patient not having idiopathic pulmonary fibrosis
US20130224306A1 (en) * 2012-02-29 2013-08-29 Gilead Sciences, Inc. Method for treating a pulmonary hypertension condition without companion diagnosis
WO2014003678A1 (en) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Pharmaceutical compositions comprising ambrisentan and solid dispersion particles containing tadalafil
US10518112B2 (en) 2014-06-18 2019-12-31 Sonivie Ltd. Method for treating secondary pulmonary hypertension
US10576083B2 (en) * 2015-08-13 2020-03-03 Cipla (UK) Limited Method of treating pulmonary arterial hypertension
AU2017296040C1 (en) 2016-07-15 2023-06-22 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
US20200238107A1 (en) 2017-03-20 2020-07-30 Sonie Vie Ltd. Pulmonary hypertension treatment method and/or system
JP2020532521A (ja) * 2017-08-30 2020-11-12 ベレロフォン パルス テクノロジーズ エルエルシー 右室及び／又は左室機能の改善のための吸入用一酸化窒素の使用
MX2020006741A (es) * 2017-12-28 2020-11-24 Bellerophon Pulse Tech Llc Uso de oxigeno y oxido nitrico inhalado para el tratamiento de la hipertension pulmonar.
EP3965767A1 (en) * 2019-05-06 2022-03-16 Actelion Pharmaceuticals Ltd Methods for treating sarcoidosis-associated pulmonary hypertension
JP2023507626A (ja) 2019-12-16 2023-02-24 テナックス・セラピューティクス，インコーポレイテッド 駆出率が保たれた心不全を伴う肺高血圧症（ＰＨ－ＨＦ－ｐＥＦ）を治療するためのレボシメンダン
RU2729033C1 (ru) * 2020-02-03 2020-08-03 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр кардиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ кардиологии" Минздрава России) Способ прогнозирования эффективности длительной специфической терапии у пациентов с идиопатической легочной гипертензией и неоперабельной хронической тромбоэмболической легочной гипертензией
EP3906928A1 (en) * 2020-05-06 2021-11-10 Noorik Biopharmaceuticals AG Treatment of pulmonary complications of coronavirus
US20230174620A1 (en) 2020-04-28 2023-06-08 Acceleron Pharma Inc. Actrii proteins and use in treating post-capillary pulmonary hypertension
EP4142731A1 (en) * 2020-04-28 2023-03-08 Noorik Biopharmaceuticals AG Treatment of pulmonary complications of coronavirus infections
CN114324900A (zh) * 2021-12-03 2022-04-12 上海市肺科医院 一种促卵泡激素的应用
EP4456897A4 (en) 2021-12-31 2025-12-10 Tenax Therapeutics Inc ORAL FORMULATIONS OF LEVOSIMENDAN FOR THE TREATMENT OF PULMONARY HYPERTENSION WITH HEART FAILURE AND PRESERVED EJECTION FRACTION
EP4648761A1 (en) * 2023-01-09 2025-11-19 scPharmaceuticals Inc. Methods of treatment using loop diuretics
EP4684777A1 (en) 2024-07-24 2026-01-28 Adalvo Limited A fixed-dose pharmaceutical composition comprising (2s)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid and (6r,12ar)-6-(1,3-benzodioxol-5-yl)-2-methyl-2,3,6,7,12,12a-hexahydropyrazino{1',2:1,6]pyrido[3,4-b]indole-1,4-dione

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4325525A (en) 1980-11-13 1982-04-20 General Motors Corporation Mounting member
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
DE4313412A1 (de) 1993-04-23 1994-10-27 Basf Ag 3-(Het)aryl-Carbonsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
HU227841B1 (en) 1997-11-12 2012-05-02 Bayer Pharma AG 2-phenyl substituted imidazotriazinones, process for their preparation and pharmaceutical compositions thereof
US6821975B1 (en) 1999-08-03 2004-11-23 Lilly Icos Llc Beta-carboline drug products
US20060292213A1 (en) * 2004-06-23 2006-12-28 Myogen, Inc. Enoximone formulations and their use in the treatment of PDE-III mediated diseases
TW200621261A (en) 2004-08-26 2006-07-01 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
JP2008528604A (ja) 2005-01-25 2008-07-31 グラクソ グループ リミテッド 抗菌剤
DK2013208T3 (da) * 2006-04-21 2011-08-15 Pfizer Prod Inc Pyridin[3,4-B]pyrazinoner
EP2091539A1 (en) * 2006-12-12 2009-08-26 Gilead Colorado, Inc. Ambrisentan combined with a renin inhibitor for hypertensive disorder
JP2010512414A (ja) 2006-12-12 2010-04-22 ギリード・コロラド・インコーポレーテッド 肺高血圧を処置するための組成物
CN101801936B (zh) 2007-07-31 2012-10-03 吉利德科罗拉多公司 安立生坦的代谢物和衍生物
WO2010062640A1 (en) 2008-10-28 2010-06-03 Gilead Colorado, Inc. Methods for treating idiopathic pulmonary fibrosis and associated complications
EA026074B1 (ru) 2010-10-15 2017-02-28 Джилид Сайэнс, Инк. Способы, включающие применение композиции амбризентана и тадалафила для лечения легочной артериальной гипертензии

Also Published As

Publication number Publication date
US20170136016A1 (en) 2017-05-18
LU93081I2 (fr) 2016-07-20
US20080139593A1 (en) 2008-06-12
PT2101777E (pt) 2015-09-18
CY2016017I2 (el) 2016-10-05
US20100152217A1 (en) 2010-06-17
HUE025355T2 (en) 2016-02-29
DK2101777T3 (en) 2015-08-17
WO2008073928A1 (en) 2008-06-19
US20150224100A1 (en) 2015-08-13
US9504685B2 (en) 2016-11-29
US9993475B2 (en) 2018-06-12
EP2101777A1 (en) 2009-09-23
ES2544724T3 (es) 2015-09-03
AU2007333115A1 (en) 2008-06-19
US20110245253A1 (en) 2011-10-06
US20130116257A1 (en) 2013-05-09
CA2669536A1 (en) 2008-06-19
JP2010512414A (ja) 2010-04-22
EP2952193A1 (en) 2015-12-09
PL2101777T3 (pl) 2015-10-30
US8377933B2 (en) 2013-02-19
US20140296244A1 (en) 2014-10-02
CY2016017I1 (el) 2016-10-05
HUS1600027I1 (hu) 2016-06-28
AU2007333115B2 (en) 2013-01-10
US9474752B2 (en) 2016-10-25
HK1218393A1 (en) 2017-02-17
CA2669536C (en) 2016-05-31
EP2101777B1 (en) 2015-05-20

Similar Documents

Publication Publication Date Title
HUS1600027I1 (hu) Kompozíció pulmonáris hipertensio kezeléséhez
PT2094708E (pt) Pirrolopirazina como inibidor da cinase syk
EP2065444A4 (en) PHOTOPOLYMERIZABLE COMPOSITION
GB0612845D0 (en) Deacidification method
GB0625586D0 (en) Composition
GB0607605D0 (en) Composition
GB0701048D0 (en) A composition
GB0621554D0 (en) Batten
EP2059135A4 (en) NOVEL COMPOSITION
GB0623619D0 (en) Composition
GB0820885D0 (en) A composition for the treatment of hypertension
GB0625430D0 (en) Composition
GB0625429D0 (en) Composition
GB0600427D0 (en) Compounds
GB0611408D0 (en) Ballast
GB0623618D0 (en) Composition
GB0500922D0 (en) A therapy for pulmonary hypertension
HK1140689A (en) Methods and compositions for treating pulmonary hypertension
HU0600193V0 (en) Latch-cover for water-network
GB0605522D0 (en) Composition
GB0617215D0 (en) Composition
GB0602260D0 (en) Composition
GB0607823D0 (en) Composition
GB0620338D0 (en) Composition
GB0609701D0 (en) Composition